273 related articles for article (PubMed ID: 19839925)
1. The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC).
Wagner TD; Yang GY
Curr Drug Targets; 2010 Jan; 11(1):67-73. PubMed ID: 19839925
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
Govindan R; Bogart J; Stinchcombe T; Wang X; Hodgson L; Kratzke R; Garst J; Brotherton T; Vokes EE
J Clin Oncol; 2011 Aug; 29(23):3120-5. PubMed ID: 21747084
[TBL] [Abstract][Full Text] [Related]
4. The role of pemetrexed combined with targeted agents for non-small cell lung cancer.
Konopa K; Jassem J
Curr Drug Targets; 2010 Jan; 11(1):2-11. PubMed ID: 19839932
[TBL] [Abstract][Full Text] [Related]
5. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.
Shen X; Denittis A; Werner-Wasik M; Axelrod R; Gilman P; Meyer T; Treat J; Curran WJ; Machtay M
Radiat Oncol; 2011 Feb; 6():17. PubMed ID: 21324160
[TBL] [Abstract][Full Text] [Related]
6. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
7. [A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].
Tredaniel J; Mornex F; Barillot I; Diaz O; Hennequin C; Le Pechoux C; Lavole A; Giraud P; Souquet PJ; Teixeira L; Vaylet F; Zalcman G; Baudrin L; Morin F; Milleron B
Rev Mal Respir; 2011 Jan; 28(1):51-7. PubMed ID: 21277474
[TBL] [Abstract][Full Text] [Related]
8. Role of pemetrexed and platinums combination in patients with non-small cell lung cancer.
Chen M; Shao W; He J; Wang D
Curr Drug Targets; 2010 Jan; 11(1):29-36. PubMed ID: 19839930
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed in advanced non-small cell lung cancer.
Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
[TBL] [Abstract][Full Text] [Related]
10. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
Joerger M; Omlin A; Cerny T; Früh M
Curr Drug Targets; 2010 Jan; 11(1):37-47. PubMed ID: 19839929
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed disodium for the treatment of NSCLC: an update.
Hsu JY; Wakelee H
Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
[TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of pemetrexed (Alimta) in lung cancer.
Socinski MA; Stinchcombe TE; Hayes DN
Semin Oncol; 2005 Apr; 32(2 Suppl 2):S16-22. PubMed ID: 15818533
[TBL] [Abstract][Full Text] [Related]
14. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
[TBL] [Abstract][Full Text] [Related]
15. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
16. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Li T; Lara PN; Mack PC; Perez-Soler R; Gandara DR
Curr Drug Targets; 2010 Jan; 11(1):85-94. PubMed ID: 19839922
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
19. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL
Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]